Medicare would cover 100% of lung cancer biomarker testing costs for eligible patients.
This bill would require Medicare to cover lung cancer biomarker testing for people diagnosed with lung cancer. It would also make sure Medicare pays 100% of the reasonable costs for these tests. This means patients would not have out-of-pocket costs for these specific tests, starting January 1, 2027.
Currently, Medicare does not explicitly require coverage for lung cancer biomarker testing, and patients may face out-of-pocket costs. If this bill becomes law, Medicare would be required to cover these tests for individuals diagnosed with lung cancer, and it would pay 100 percent of the reasonable charges. This means patients would have no direct costs for these specific tests, starting January 1, 2027.
HR 6321 · 119th Congress · AI Summary by gemini-2.5-flash · 10/10
Sign in to see your representatives' phone numbers
3 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.